Impact of orally disintegrating olanzapine on use of intramuscular antipsychotics, seclusion, and restraint in an acute inpatient psychiatric setting [3]

Journal of Clinical Psychopharmacology

Volumn 26, Issue 3, 2006, Pages 333-335

  Simpson Jr , Joseph R ^a   Thompson, Christopher R ^b   Beckson, Mace ^c,d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; HALOPERIDOL; LORAZEPAM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; ZIPRASIDONE;

ADULT; AGGRESSION; AGITATION; CONFIDENTIALITY; DISEASE SEVERITY; DRUG ADMINISTRATION ROUTE; DRUG CHOICE; DRUG SOLUBILITY; DRUG USE; ETHICS; FEMALE; HOSPITAL PATIENT; HUMAN; IMMOBILIZATION; INFORMED CONSENT; LETTER; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; METHODOLOGY; MORALITY; PRIORITY JOURNAL; PSYCHOSIS; SOCIAL ISOLATION; TREATMENT REFUSAL; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PSYCHOMOTOR AGITATION; PSYCHOTIC DISORDERS; RESTRAINT, PHYSICAL;

EID: 33744467400     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000222516.56143.b1     Document Type: Letter

References (12)

1. Buckley PF. The role of typical and atypical antipsychotic medications in the management of agitation and aggression. J Clin Psychiatry. 1999;60(suppl 10):52-60.
2. Ayd FJ Jr. A survey of drug-induced extra pyramidal reactions. JAMA. 1961;175:1054-1060.
3. Van Putten T, Marder SR. Behavioral toxicity of antipsychotic drugs. J Clin Psychiatry. 1987;48(suppl 9):13-19.
4. Keck PE Jr, Pope HG Jr, Cohen BM, et al. Risk factors for neuroleptic malignant syndrome: a case-control study. Arch Gen Psychiatry. 1989;46:914-918.
5. Casey DE. Motor and mental aspects of extrapyramidal syndromes. Int Clin Psychopharmacol. 1995;10(suppl 3):105-114.
6. Czekalla J, Beasley CM Jr, Dellva MA, et al. Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. J Clin Psychiatry. 2001;62:191-198.
7. Munetz MR, Geller JL. The least restrictive alternative in the postinstitutional era. Hosp Community Psychiatry. 1993;44:967-973.
8. Brennan W. We don't have to take this: dealing with violence at work. Nurs Stand. 2000;14(suppl 28):3-17.
9. Chengappa KNR, Levine J, Ulrich R, et al. Impact of risperidone on seclusion and restraint at a state psychiatric hospital. Can J Psychiatry. 2000;45:827-832.
10. Currier GW, Simpson GM. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry. 2001;62:153-157.
11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition, Text Revision. Washington, DC; American Psychiatric Association; 2000.
12. Zyprexa Zydis Product Information. Indianapolis, IN: Eli Lilly and Co; June 2005.